Abstract
Background: Population-based studies examining the prevalence of trigeminal neuralgia (TN) and persistent idiopathic facial pain (PIFP) are rare, and data on TN prevalence in Türkiye are very limited, with the prevalence of PIFP being unknown. This study aimed to determine the prevalence of TN and PIFP in Türkiye. Materials and Methods: This population-based epidemiological study has a cross-sectional and descriptive design, and it was carried out in Afyonkarahisar, Türkiye. Participants aged 18 years and older were screened by using a self-assessment form to determine potential patients with TN or PIFP. Results: A total of 19,237 individuals were included in this study, of which 17,223 responded to the survey questions. TN was diagnosed in 17 individuals, and the prevalence of TN was calculated as 98.5 per 100,000. PIFP was diagnosed in 35 patients, and the prevalence of PIFP was calculated as 202 per 100,000. The mean age of the patients with TN was 54.29 ± 12.98 years, the mean age of patients with PIFP was 49.80 ± 16.10 years, and the female-to-male ratio was 1.13/1 for TN and 2.18/1 for PIFP. Conclusion: The prevalence of PIFP in Türkiye has been reported for the first time by this study. Additionally, a much higher prevalence of TN was found when compared to previous study.
Journal Section:
Original Paper
References
1.
Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition
. Cephalalgia
. 2018
:1
–211
. 2.
Olesen
J
. Preface to the second edition
. Cephalalgia
. 2004
;24
:9
–10
. 3.
MacDonald
BK
, Cockerell
OC
, Sander
JW
, Shorvon
SD
. The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK
. Brain
. 2000
;123(Pt 4)
:665
–76
. 4.
Sjaastad
O
, Bakketeig
LS
. The rare, unilateral headaches. Vågå study of headache epidemiology
. J Headache Pain
. 2007
;8
(1
):19
–27
. 5.
Schwaiger
J
, Kiechl
S
, Seppi
K
, Sawires
M
, Stockner
H
, Erlacher
T
, et al. Prevalence of primary headaches and cranial neuralgias in men and women aged 55–94 Years (bruneck study)
. Cephalalgia
. 2009
;29
(2
):179
–87
. 6.
Mueller
D
, Obermann
M
, Yoon
MS
, Poitz
F
, Hansen
N
, Slomke
MA
, et al. Prevalence of trigeminal neuralgia and persistent idiopathic facial pain: a population-based study
. Cephalalgia
. 2011
;31
(15
):1542
–8
. 7.
Bölük
C
, Türk Börü
Ü
, Taşdemir
M
. The prevalence of trigeminal neuralgia in Turkey: a population-based study
. Neurol Res
. 2020
;42
(11
):968
–72
. 8.
Hall
GC
, Carroll
D
, Parry
D
, McQuay
HJ
. Epidemiology and treatment of neuropathic pain: the UK primary care perspective
. Pain
. 2006
;122
(1–2
):156
–62
. 9.
Katusic
S
, Beard
CM
, Bergstralth
E
, Kurland
LT
. Incidence and clinical features of trigeminal neuralgia, Rochester, Minnesota, 1945–1984
. Ann Neurol
. 1990
;27
(1
):89
–95
. 10.
Lee
CH
, Jang
HY
, Won
HS
, Kim
JS
, Kim
YD
. Epidemiology of trigeminal neuralgia: an electronic population health data study in Korea
. Korean J Pain
. 2021
;34
(3
):332
–8
. 11.
El-Tallawy
HN
, Farghaly
WM
, Rageh
TA
, Shehata
GA
, Abdel Hakeem
MN
, Badry
R
, et al. Prevalence of trigeminal neuralgia in Al-Quseir city (Red sea Governorate), Egypt
. Clin Neurol Neurosurg
. 2013
;115
(9
):1792
–4
. 12.
Harris
W
. An analysis of 1,433 cases of paroxysmal trigeminal neuralgia (TRIGEMINAL-TIC) and the end-results of gasserian alcohol injection
. Brain
. 1940
;63
(3
):209
–24
. 13.
Smyth
P
, Greenough
G
, Stommel
E
. Familial trigeminal neuralgia: case reports and review of the literature
. Headache: J Head Face Pain
. 2003
;43
(8
):910
–5
. 14.
Terrence
CT
, Fromm
GH
. Trigeminal neuralgia and other facial neuralgias
. In: Olesen
J
, Tfelt-Hansen
P
, Welch
KMA
, editors. The headaches
. New York
: Raven Press
; 1993
. p. 773
–86
.15.
Hooge
JP
, Redekop
WK
. Trigeminal neuralgia in multiple sclerosis
. Neurology
. 1995
;45
(7
):1294
–6
. 16.
Solaro
C
, Brichetto
G
, Amato
MP
, Cocco
E
, Colombo
B
, D’Aleo
G
, et al. The prevalence of pain in multiple sclerosis: a multicenter cross-sectional study
. Neurology
. 2004
;63
(5
):919
–21
. 17.
Macfarlane
TV
, Blinkhorn
AS
, Davies
RM
, Kincey
J
, Worthington
HV
. Oro-facial pain in the community: prevalence and associated impact
. Community Dent Oral Epidemiol
. 2002
;30
(1
):52
–60
. 18.
Aggarwal
VR
, Macfarlane
GJ
, Farragher
TM
, McBeth
J
. Risk factors for onset of chronic oro-facial pain – results of the North Cheshire oro-facial pain prospective population study
. Pain
. 2010
;149
(2
):354
–9
. 19.
Koopman
JSHA
, Dieleman
JP
, Huygen
FJ
, de Mos
M
, Martin
CGM
, Sturkenboom
MCJM
. Incidence of facial pain in the general population
. Pain
. 2009
;147
(1–3
):122
–7
. 20.
McMillan
AS
, Wong
MCM
, Zheng
J
, Lam
CLK
. Prevalence of orofacial pain and treatment seeking in Hong Kong Chinese
. J Orofac Pain
. 2006
;20
(3
):218
–25
.21.
Obermann
M
, Holle
D
, Katsarava
Z
. Trigeminal neuralgia and persistent idiopathic facial pain
. Expert Rev Neurother
. 2011
;11
:1619
–29
. 22.
Volker
B
, Arne
M
. Praxisbuch Kopf- und Gesichtsschmerzen
. 1st edn.München
: Urban & Fischer
; 2002
.23.
Dao
TT
, LeResche
L
. Gender differences in pain
. J Orofac Pain
. 2000
;14
(3
):169
–95
; discussion 184–95.24.
25.
Sekaran
Uma
. Research Methods for Business: A Skills Development Approach
. Wiley
; 2003
.© 2024 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2024
You do not currently have access to this content.
